Nov 21,2023

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans. Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Medical has proactively pursued a funding strategy that minimizes dilution and, the Company believes, aligns with the best interests of its valued shareholders. This $10 million credit facility, structured to be non-dilutive, empowers the Company to draw down a maximum of $1 million per month, providing a steady and controlled infusion of capital to support Nemaura Medical’s commercialization initiatives.

FUNDING NON-DILUTIVE CREDIT FACILITY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 21,2023

New Research Sheds Light on Mediators of Improved Outcomes in Dario Users

DarioHealth announced two new analyses recently presented by Sanofi U.S. demonstrating two mediators associated with improved clinical and economic in Dario users. Presentations by Sanofi U.S. at the Diabetes Technology Society (DTS) annual conference, held Nov. 2 – 4, examined real-world data from matched Dario users and non-users with type 2 diabetes to determine the association of medication adherence from Dario's digital health solution with blood glucose control. Dario users saw an overall clinically significant reduction in HbA1c and an associated 10.6% improvement in medication adherence. Sanofi also presented research at ISPOR Europe 2023, held on November 12-15, 2023, of a new analysis showing more frequently engaged Dario users were associated with 10% reduction in all-cause healthcare resource use over 100 days and were 15% less likely to incur related charges. Engagement was defined by activities meaningful to diabetes management, such as taking a blood glucose reading; inputting an insulin dose; recording physical activity or tagging a meal. This new analysis provides additional information from previously reported study results demonstrating Dario's ability to contribute to a reduction in all-cause healthcare utilization by 9% including inpatient hospitalizations by 23% compared to non-users at 12 months.

CLINICAL STUDY

#coaching

#dtx

View Analyst & Ambassador Comments
Go to original news
Nov 21,2023 TOP STORY

Medtronic reports second quarter fiscal 2024 financial results

Medtronic announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Medtronic reported Q2 worldwide revenue of $7.984 billion, an increase of 5.3% as reported and 5.0% on an organic basis YoY. Diabetes revenue of $610 million increased 9.7% as reported and 6.7% organic YoY. Non-U.S. Developed Markets grew mid-teens on continued MiniMed™ 780G system adoption and increased CGM attachment rates. First full quarter of the U.S. launch of MiniMed™ 780G system resulted in low-thirties sequential growth in U.S. Diabetes pump revenue. Overall, U.S. Diabetes declined mid-single digits year-over-year on customer attrition versus the prior year. Medtronic during the quarter has also shared the FDA approlval of its stand-alone CGM Simplera, and began the phased launch for it.

View Analyst & Ambassador Comments
Go to original news
Nov 22,2023

MEMS, Novo Nordisk and Roche launch ‘Changing Diabetes® in Children’ project in Malaysia to improve care for children and young adults below the age of 25 living with type 1 diabetes

Novo Nordisk today announced a partnership with the Malaysian Endocrine and Metabolic Society (MEMS) and Roche Diagnostics Malaysia (Roche) to launch the Changing Diabetes® in Children (CDiC) project in Malaysia – a long-term initiative with a dedicated focus on improving the quality of care for children and young adults with type 1 diabetes. Children and young adults who have type 1 diabetes in Malaysia will receive free glucose monitoring supplies (glucometer and glucose test strips) – a significant advance in the management of diabetes in children and young adults. With its launch in Malaysia, CDiC will contribute to improving access to care, in line with this year’s World Diabetes Day theme of “Access to Diabetes Care”.

COLLABORATION PARTNERSHIP

#institution

#bgm

View Analyst & Ambassador Comments
Go to original news
Nov 17,2023

Dexcom launches eye-opening diabetes research around HCL perceptions

Dexcom have released new market research which found 79% of people struggle to keep their glucose levels in range and almost half (45%) do not understand what a Hybrid Closed Loop System (HCL) is and its benefits. The research follows the new Technology Appraisal (TA) from NICE which provides detailed guidance for hybrid closed loop systems usage. It impacts an eligible population of over 150,000 people living with type 1 diabetes in England, providing access to HCL systems. Head of market access at Dexcom, Shay Speakman-Brown, spoke to exclusively to Digital Health News about the latest research, including what the benefits of a HCL will be for patients and clinicians.

#closed loop

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023

BeatO to launch physical touchpoints in several micro-markets

BeatO announced that it would be launching physical touchpoints by collaborating with leading doctors in several micro-markets. With the launch of five such clinics across Delhi-NCR on the occasion of World Diabetes Day on Tuesday, BeatO will soon cover leading cities across Uttar Pradesh, Madhya Pradesh, Rajasthan, Gujarat, and Odisha over the next six months. After creating the BeatO App which empowers more than two million diabetes users with a range of products and digital services, BeatO is taking a step forward by increasing the range of options available to patients who require physical touchpoints in their diabetes control and treatment regimen. A physical approach would be especially useful when onboarding patients with relatively complex conditions, where a physical visit can be seamlessly followed up with digital consultations, ensuring comprehensive, convenient, and proactive care.

PRODUCT

#virtual care

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023

Withings Health Solutions Launches Body Pro 2, Revolutionizing The Detection Of Early Diabetes Complications With The Next-Gen Cellular Scale

On World Diabetes Day, Withings Health Solutions provides a leap forward for the digital health industry with the launch of Body Pro 2, a revolutionary device redefining the nature and use of cellular-connected smart scales. Body Pro 2's first module is prescription-only (Rx) and aims to improve the way patients with diabetes are taken care of. With this module care teams can monitor one of the biggest challenges in diabetes, diabetic foot health, which is often overlooked. By monitoring patients' Electrochemical Skin Conductance (ESC), the scale may help to detect early signs of Diabetic Peripheral Neuropathies (DPN) and assess the risk for diabetic foot ulcers. Additional patient-engagement features in the offerings from Body Pro 2 includes communication with care teams, health nudges, motivational messages, and more.

PRODUCT

#connected device

#smart scale

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023 TOP STORY

Capital Rx and Vida Health Partner to Launch Rx Activate, a High-Touch Chronic Condition Management Program

Capital Rx, the full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA) is partnering with Vida Health to launch Rx Activate and provide its clients with access to additional resources and options to help manage cardiometabolic conditions via personalized virtual care. Rx Activate, leveraging JUDI which is Capital Rx's enterprise health platform, includes high-touch medication management supported by member service to build trust with providers and patients and help bring down the total cost of care. Plan members would have access to Vida’s providers and resources for cardiometabolic conditions, including hyperlipidemia, hypertension, diabetes, congestive heart failure, mental health and weight management. Plan sponsors and administrators can choose from three Rx Activate options, which include devices, labs, and medication prescribing for range of chronic conditions.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Nov 13,2023

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

Nemaura Medical released its financial results for the quarter ended September 30, 2023 and provided a business update. Research and development expenses were reported as $491,803 in this quarter, compared to $257,061 in the same period in 2022. Net loss was around $1.2 million USD for the three months ended September 30, 2023, compared to $3.8 million in the same period last year. During this quarter, the Company continued to support its UK licensee with its endeavours to obtain reimbursement for the sensors in the UK. the Company’s BEATdiabetes offering in readiness for a commercial launch is in due course. Nemaura also received approval from the Saudi Arabia Food and Drug Agency for marketing of sugarBEAT in the Kingdom of Saudi Arabia (KSA), with support from the Company’s licensee in the region, TP MENA.

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES